Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Nasdaq

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Health and Me on MSN

This widely used dementia drug may raise stroke risk in all patients, study finds

A large UK study of over 165,000 dementia patients finds risperidone raises stroke risk in all users, prompting concerns over prescribing, monitoring, and dementia care guidelines. Keep reading for ...
Seeking Alpha

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help ...